A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

In this article SMMT Follow your favorite stocksCREATE FREE ACCOUNT Piotr Swat | Lightrocket | Getty Images An experimental lung cancer drug from Akeso and

Tag: cut

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Behind-the-Scenes: Evacuation from St Helena and Ascension

Why Trump reversed course to fast-track psychedelic drugs for mental healthcare

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

How to Get Grandparents and Grandkids to Connect

‘Hacks’: Why Friends Don’t Have to Be the Same Age

8 Amazing Emotional Benefits of Playing an Instrument